- $281.93m
- $296.25m
- $86.67m
- 55
- 28
- 71
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.15 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.25 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.22% | ||
| Return on Equity | -22.95% | ||
| Operating Margin | -7.75% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 15.59 | 24.14 | 45.84 | 64.99 | 86.67 | 105.1 | 111.2 | 49.09% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
Directors
- Ronald Nixon CHM (65)
- Zachary Fleming CEO (47)
- Michael McNeil CFO (56)
- Christopher Morrison CEX (50)
- Shawn Bowman OTH (45)
- Roszell Mack DRC
- Ann Salamone DRC (70)
- Eric Tanzberger DRC (52)
- Robert DeSutter IND (52)
- Sara Ortwein IND (62)
- James Stuckert IND (83)
- Kenneth Thorpe IND (64)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 14th, 2001
- Public Since
- April 7th, 1994
- No. of Shareholders
- 310
- No. of Employees
- 141
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 8,887,984
- Address
- 1200 Summit Avenue, Suite 414, FORT WORTH, 76102
- Web
- https://sanaramedtech.com/
- Phone
- +1 8175292300
- Auditors
- Weaver & Tidwell LLP
Upcoming Events for SMTI
Q1 2025 Sanara Medtech Inc Earnings Release
Sanara Medtech Inc Annual Shareholders Meeting
Sanara Medtech Inc Annual Shareholders Meeting
Q2 2025 Sanara Medtech Inc Earnings Release
Similar to SMTI
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the Sanara Medtech share price?
As of Today at 23:04 UTC, shares in Sanara Medtech are trading at $31.72. This share price information is delayed by 15 minutes.
How has the Sanara Medtech share price performed this year?
Shares in Sanara Medtech last closed at $31.72 and the price had moved by -1.52% over the past 365 days. In terms of relative price strength the Sanara Medtech share price has underperformed the S&P500 Index by -9.1% over the past year.
What are the analyst and broker recommendations for Sanara Medtech?
The overall consensus recommendation for Sanara Medtech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sanara Medtech dividend yield?
Sanara Medtech does not currently pay a dividend.
Does Sanara Medtech pay a dividend?
Sanara Medtech does not currently pay a dividend.
When does Sanara Medtech next pay dividends?
Sanara Medtech does not currently pay a dividend.
How do I buy Sanara Medtech shares?
To buy shares in Sanara Medtech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sanara Medtech?
As of the previous close price of $31.72, shares in Sanara Medtech had a market capitalisation of $281.93m.
Where are Sanara Medtech shares listed?
Here are the trading details for Sanara Medtech:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SMTI
What kind of share is Sanara Medtech?
Based on an overall assessment of its quality, value and momentum Sanara Medtech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sanara Medtech share price forecast for 2025?
The analyst consensus target price for shares in Sanara Medtech is $48.50. That is 52.9% above the last closing price of $31.72.
Analysts covering Sanara Medtech currently have a consensus Earnings Per Share (EPS) forecast of -$1.78 for the next financial year.
Find out moreWhat is the trend in the Sanara Medtech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sanara Medtech. Over the past six months, its share price has outperformed the S&P500 Index by +5.47%.
As of the last closing price of $31.72, shares in Sanara Medtech were trading -3.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sanara Medtech PE Ratio?
The Sanara Medtech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $31.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sanara Medtech?
Sanara Medtech's management team is headed by:
- Ronald Nixon - CHM
- Zachary Fleming - CEO
- Michael McNeil - CFO
- Christopher Morrison - CEX
- Shawn Bowman - OTH
- Roszell Mack - DRC
- Ann Salamone - DRC
- Eric Tanzberger - DRC
- Robert DeSutter - IND
- Sara Ortwein - IND
- James Stuckert - IND
- Kenneth Thorpe - IND